

ASX Announcement

24 April 2023

Oral presentation at The Mayo Clinic IMPACT Course 2023

Key Highlights

- ✓ Oral presentation presented at The Mayo Clinic IMPACT Course 2023 by Dr Frank Weilert from Waikato Hospital, New Zealand; and
- ✓ The presentation covered an analysis of 49 patients implanted with the OncoSil™ device in Australia and New Zealand from August 2017 to January 2023.

Sydney, Australia – 24 April 2023: The Board of OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce the findings of an oral presentation at The Mayo Clinic IMPACT (Innovations in Management of Pancreatic Conditions and Therapies) Course 2023 presented by Dr Frank Weilert from Waikato Hospital, New Zealand, held in New York on Friday 21 April 2023.

The oral presentation reviewed the clinical outcomes of 49 patients who were implanted with the OncoSil™ device at Royal Adelaide Hospital in Australia and Waikato Hospital, New Zealand. These patients were also treated with either FOLFIRINOX or gemcitabine and nab-paclitaxel chemotherapy. The key data presented included:

- ✓ Local disease control in patients 12 weeks post-implant was 96%
- ✓ 15 patients (31%) had tumour downstaging and were technically resectable; and
- ✓ Technical success of OncoSil™ implantation was 100% with no acute complications.

The oral presentation follows a case study published in the New Zealand Medical Journal of a patient treated with the OncoSil™ device in November 2020 who underwent a surgical resection in November 2021. The case study reported that follow up CT scans showed no recurrent disease and the patient remains well since undergoing surgery.

OncoSil Medical's CEO and Managing Director, Mr Nigel Lange said:

"The presentation of this data covering two treatment centres in Australia and New Zealand demonstrates the key benefits of the OncoSil™ device for patients with Locally Advanced Pancreatic Cancer."

-ENDS-

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

| | | |
|---|--|---|
| Mr Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 16096424981 | Mr Brian Leedman Non-executive Director E: brian.leedman@oncosil.com T: +61 (0) 412 281 780 | Mr Karl Pechmann CFO & Company Secretary E: karl.pechmann@oncosil.com T: +61 2 9223 3344 |
|---|--|---|

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$3b.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.